Summary
Global Markets Direct’s, ‘Glenmark Pharmaceuticals Ltd. - Product Pipeline Review - 2016’, provides an overview of the Glenmark Pharmaceuticals Ltd.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Glenmark Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Glenmark Pharmaceuticals Ltd.
- The report provides overview of Glenmark Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Glenmark Pharmaceuticals Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Glenmark Pharmaceuticals Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Glenmark Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Glenmark Pharmaceuticals Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glenmark Pharmaceuticals Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Glenmark Pharmaceuticals Ltd. Snapshot 5
Glenmark Pharmaceuticals Ltd. Overview 5
Key Information 5
Key Facts 5
Glenmark Pharmaceuticals Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Glenmark Pharmaceuticals Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Glenmark Pharmaceuticals Ltd. - Pipeline Products Glance 13
Glenmark Pharmaceuticals Ltd. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Glenmark Pharmaceuticals Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Glenmark Pharmaceuticals Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Glenmark Pharmaceuticals Ltd. - Drug Profiles 17
crofelemer DR 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
GSP-301 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
GBR-830 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
GRC-17536 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
GBR-1302 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GBR-900 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
GRC-27864 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GBR-1342 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
GBR-600 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule to Antagonize TRPM8 for Neuropathic Pain 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Glenmark Pharmaceuticals Ltd. - Pipeline Analysis 29
Glenmark Pharmaceuticals Ltd. - Pipeline Products by Target 29
Glenmark Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 31
Glenmark Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 32
Glenmark Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 33
Glenmark Pharmaceuticals Ltd. - Recent Pipeline Updates 35
Glenmark Pharmaceuticals Ltd. - Dormant Projects 40
Glenmark Pharmaceuticals Ltd. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
GRC-15300 41
GRC-6211 41
oglemilast 41
revamilast 41
Glenmark Pharmaceuticals Ltd. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46
List of Tables
Glenmark Pharmaceuticals Ltd., Key Information 5
Glenmark Pharmaceuticals Ltd., Key Facts 5
Glenmark Pharmaceuticals Ltd. - Pipeline by Indication, 2016 8
Glenmark Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016 9
Glenmark Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016 10
Glenmark Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2016 11
Glenmark Pharmaceuticals Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 12
Glenmark Pharmaceuticals Ltd. - Phase III, 2016 13
Glenmark Pharmaceuticals Ltd. - Phase II, 2016 14
Glenmark Pharmaceuticals Ltd. - Phase I, 2016 15
Glenmark Pharmaceuticals Ltd. - Preclinical, 2016 16
Glenmark Pharmaceuticals Ltd. - Pipeline by Target, 2016 30
Glenmark Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016 31
Glenmark Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016 32
Glenmark Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016 34
Glenmark Pharmaceuticals Ltd. - Recent Pipeline Updates, 2016 35
Glenmark Pharmaceuticals Ltd. - Dormant Developmental Projects,2016 40
Glenmark Pharmaceuticals Ltd. - Discontinued Pipeline Products, 2016 41
Glenmark Pharmaceuticals Ltd., Subsidiaries 42
List of Figures
Glenmark Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2016 7
Glenmark Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016 9
Glenmark Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016 10
Glenmark Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2016 11
Glenmark Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2016 29
Glenmark Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016 31
Glenmark Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016 32
Glenmark Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 33
